Biolinq Shine, Insulin Icodec, and Eli Lilly's Pipeline
Oct 14, 04:00 PM
Share
Subscribe
Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!
In this episode, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, explore 3 significant developments shaping diabetes care: a novel glucose-sensing technology, the return of once-weekly insulin icodec to the US Food and Drug Administration (FDA), and changes to Eli Lilly’s metabolic research pipeline.
00:00:01 Introduction
00:00:18 The Biolinq Shine
00:05:59 The Practicality of Monitoring Glucose
00:06:55 Wishlist for the Biolinq's Future
00:08:38 Insulin Icodec Resubmission
00:10:21 Benefits of Once-Weekly Insulin
00:14:00 International Success Stories
00:15:28 Eli Lilly Cancels Bimagrumab for T2D
00:18:36 Bimagrumab Still in Testing for Obesity
00:22:49 Outro
In this episode, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, explore 3 significant developments shaping diabetes care: a novel glucose-sensing technology, the return of once-weekly insulin icodec to the US Food and Drug Administration (FDA), and changes to Eli Lilly’s metabolic research pipeline.
00:00:01 Introduction
00:00:18 The Biolinq Shine
00:05:59 The Practicality of Monitoring Glucose
00:06:55 Wishlist for the Biolinq's Future
00:08:38 Insulin Icodec Resubmission
00:10:21 Benefits of Once-Weekly Insulin
00:14:00 International Success Stories
00:15:28 Eli Lilly Cancels Bimagrumab for T2D
00:18:36 Bimagrumab Still in Testing for Obesity
00:22:49 Outro